Akut mieloid leukémia (AML): vizsgálatok itt: Ausztria
14 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 14.. Ask the study team whether a trial fits you.
- 3. fázisTaking peoplePhase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
- Where
- Innsbruck, Linz, Rankweil, Salzburg, Vienna
- Életkor
- 18 év to 75 év
- People
- 650 worldwide
- Run by
- University of Ulm
See details and how to joinNCT04628026 · EU 2023-507518-28-00 - 3. fázisTaking peopleBleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
- Where
- Feldkirch, Linz, Vienna
- Életkor
- 18 év and over
- People
- 875 worldwide
- Run by
- Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07223814 · EU 2025-522767-15-00 - 3. fázisTaking peopleA Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Where
- Linz, Salzburg, Vienna, Wels
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06852222 · EU 2024-520154-38-00 - 2/3. fázisTaking peopleA Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
- Where
- Graz, Linz, St. Poelten, Vienna
- Életkor
- 18 év and over
- People
- 660 worldwide
- Run by
- AbbVie
See details and how to joinNCT07581002 · EU 2025-523724-47-00 - 3. fázisTaking peopleA study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
- Where
- Feldkirch, Innsbruck, Salzburg, Vienna
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
See details and how to join2024-512753-24-00 - 3. fázisTaking peopleStudy of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- Where
- Graz, Innsbruck, Klagenfurt Am Woerthersee, Leoben, Linz, St. Poelten, Vienna
- Életkor
- 12 év and over
- People
- 468 worldwide
- Run by
- Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00 - 1. fázisTaking peopleZiftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
- Where
- Vienna
- Életkor
- 0 év to 21 év
- People
- 20 worldwide
- Run by
- PedAL BCU, LLC
See details and how to joinNCT06376162 · EU 2023-505262-28-00 - 2. fázisTaking people(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Where
- Vienna
- Életkor
- 18 év and over
- People
- 140 worldwide
- Run by
- Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00 - 3. fázisTaking peopleRevumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- Where
- Feldkirch, Linz, Salzburg, Vienna
- Életkor
- 18 év and over
- People
- 448 worldwide
- Run by
- Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT06652438 · EU 2024-512733-32-00 - 2. fázisTaking peopleRevumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)
- Where
- Vienna
- Életkor
- Up to 64 év
- People
- 31 worldwide
- Run by
- Pediatric Research International GmbH
See details and how to join2025-521390-14-00 - 2. fázisCsak meghívásosA Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
- Where
- Vienna
- Életkor
- 18 év and over
- People
- 332 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT04093570 · EU 2024-516293-29-01 - 3. fázisTaking peopleAn Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
- Where
- Linz, Vienna, Wels
- Életkor
- 18 év and over
- People
- 245 worldwide
- Run by
- Servier Affaires Médicales
See details and how to joinNCT05907057 · EU 2022-501709-11-00 - No phaseTaking peopleRegistry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project
- Where
- Graz, Innsbruck, Linz, Rankweil, Salzburg, Vienna
- Életkor
- 18 év and over
- People
- 50 000 worldwide
- Run by
- University of Ulm
See details and how to joinNCT01252485 - 3. fázisTaking peopleIvosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
- Where
- Feldkirch, Salzburg, Vienna
- Életkor
- 18 év and over
- People
- 227 worldwide
- Run by
- Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07075016